Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 597–604 | Cite as

Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy

  • Elisabeth Odin
  • Arvid Sondén
  • Bengt Gustavsson
  • Göran Carlsson
  • Yvonne Wettergren
Research Article

Abstract

Colorectal cancer is commonly treated with 5-fluorouracil and 5-formyltetrahydrofolate (leucovorin). Metabolic action of leucovorin requires several enzymatic steps that are dependent on expression of corresponding coding genes. To identify folate pathway genes with possible impact on leucovorin metabolism, a retrospective study was performed on 193 patients with stage III colorectal cancer. Relative expression of 22 genes putatively involved in leucovorin transport, polyglutamation and metabolism was determined in tumor and mucosa samples using quantitative real-time polymerase chain reaction. After surgery, patients received adjuvant 5-fluorouracil-based bolus chemotherapy with leucovorin during six months, and were followed for 3 to 5 years. Cox regression analysis showed that high tumoral expression of the genes SLC46A1/PCFT (proton-coupled folate transporter) and SLC19A1/RFC-1 (reduced folate carrier 1) correlated significantly (p < 0.001 and p < 0.01, respectively) with a decreased risk of recurrent disease, measured as disease-free survival (DFS). These two genes are involved in the transport of folates into the cells and each functions optimally at a different pH. We conclude that SLC46A1/PCFT and SLC19A1/RFC-1 are associated with DFS of patients with colorectal cancer and hypothesize that poor response to 5-fluorouracil plus leucovorin therapy in some patients may be linked to low expression of these genes. Such patients might need a more intensified therapeutic approach than those with high gene expression. Future prospective studies will determine if the expression of any of these genes can be used to predict response to leucovorin.

Notes

Acknowledgments

We thank J Flach, I Palmgren and M Akerström for their technical assistance, H Björkqvist and A-L Helminen for the collection of surgical samples and L Munro and B Sjöberg for their work with the clinical database. We also thank personnel at the Genomics Core Facility for performing the quantitative gene expression analysis, and personnel at the Bioin-formatics Core Facility for their help with the statistical analyses. This work was supported by grants from the Swedish Cancer Society, the Health and Medical Care Committee of the Regional Executive Board Region Västra Götaland, Isofol Medical AB, the Assar Gabrielsson Foundation for Cancer Research, the Gustaf V Jubilee Clinic Foundation for Cancer Research, the Anna-Lisa and Bror Björnsson Foundation and the Ingabritt and Arne Lundberg Foundation.

Supplementary material

10020_2015_2101597_MOESM1_ESM.pdf (228 kb)
Supplementary material, approximately 227 KB.

References

  1. 1.
    Thirion P, et al. (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol. 22:3766–75.CrossRefGoogle Scholar
  2. 2.
    Porcelli L, et al. (2011) The impact of folate status on the efficacy of colorectal cancer treatment. Curr. Drug Metab. 12:975–84.CrossRefGoogle Scholar
  3. 3.
    Kaiyawet N, Rungrotmongkol T, Hannongbua S. (2013) Effect of halogen substitutions on dUMP to stability of thymidylate synthase/dUMP/mTHF ternary complex using molecular dynamics simulation. J. Chem. Inf. Model. 53:1315–23.CrossRefGoogle Scholar
  4. 4.
    Taflin H, Wettergren Y, Odin E, Derwinger K. (2014) Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages. Cancer Chemother. Pharmacol. 74:1167–74.CrossRefGoogle Scholar
  5. 5.
    Houghton JA, et al. (1990) Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res. 50:3940–6.PubMedGoogle Scholar
  6. 6.
    Galivan J, et al. (2000) Glutamyl hydrolase. pharmacological role and enzymatic characterization. Pharmacol. Ther. 85:207–15.CrossRefGoogle Scholar
  7. 7.
    Shane B. (2010) Folate Chemistry and Metabolism. 2nd edition. In: Folate in Health and Disease. Bailey LB (ed.) CRC Press, Taylor & Francis Group, Boca Raton, FL, pp 1–24.Google Scholar
  8. 8.
    Hooijberg JH, et al. (2003) The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65:765–71.CrossRefGoogle Scholar
  9. 9.
    Lowe KE, et al. (1993) Regulation of folate and one-carbon metabolism in mammalian cells. II. Effect of folylpoly-gamma-glutamate synthetase substrate specificity and level on folate metabolism and folylpoly-gamma-glutamate specificity of metabolic cycles of one-carbon metabolism. J. Biol. Chem. 268:21665–73.PubMedGoogle Scholar
  10. 10.
    Tibbetts AS, Appling DR. (2010) Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu. Rev. Nutr. 30:57–81.CrossRefGoogle Scholar
  11. 11.
    Field MS, Szebenyi DM, Stover PJ. (2006) Regulation of de novo purine biosynthesis by methenyltetrahydrofolate synthetase in neuroblastoma. J. Biol. Chem. 281:4215–21.CrossRefGoogle Scholar
  12. 12.
    Kohls D, Sulea T, Purisima EO, MacKenzie RE, Vrielink A. (2000). The crystal structure of the formiminotransferase domain of formiminotransferase-cyclodeaminase: implications for substrate channeling in a bifunctional enzyme. Structure. 15:35–46.CrossRefGoogle Scholar
  13. 13.
    Herbig K, et al. (2002) Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses. J. Biol. Chem. 277:38381–9.CrossRefGoogle Scholar
  14. 14.
    Krupenko NI, et al. (2010) ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J. Biol. Chem. 285:23056–63.CrossRefGoogle Scholar
  15. 15.
    Nzila A, Ward SA, Marsh K, Sims PF, Hyde JE (2005) Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium. Trends Parasitol. 21:334–9.CrossRefGoogle Scholar
  16. 16.
    Baggott JE, Tamura T (2001) Metabolism of 10-formyldihydrofolate in humans. Biomed. Pharmacother. 55:454–7.CrossRefGoogle Scholar
  17. 17.
    Lee SG, Lutz S, Benkovic SJ (2003) On the structural and functional modularity of glycinamide ribonucleotide formyltransferases. Protein Sci. 12:2206–14.CrossRefGoogle Scholar
  18. 18.
    Sinha A, et al. (2014) Biochemical characterization of pathogenic mutations in human mitochondrial methionyl-tRNA formyltransferase. J. Biol. Chem. 289:32729–41.CrossRefGoogle Scholar
  19. 19.
    Chen L, et al. (1996) Purification and properties of human cytosolic folylpoly-gamma-glutamate synthetase and organization, localization, and differential splicing of its gene. J. Biol. Chem. 271:13077–87.CrossRefGoogle Scholar
  20. 20.
    Carlsson G, et al. (1990) Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. Eur. J. Cancer. 26:874–6.CrossRefGoogle Scholar
  21. 21.
    Sorbye H, Dahl O. (2003) Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol. 42:827–31.CrossRefGoogle Scholar
  22. 22.
    Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 88:1739–57.CrossRefGoogle Scholar
  23. 23.
    Sadahiro S, et al. (2010) Molecular determinants of folate levels after leucovorin administration in colorectal cancer. Cancer Chemother. Pharmacol. 65:735–42.Google Scholar
  24. 24.
    Therneau T. (2013) A Package for Survival Analysis in S. R package version 2.37-4. Version 2.38-3 available from: https://doi.org/CRAN.R-project.org/package=survival
  25. 25.
    Zhao R, Matherly LH, Goldman ID. (2009) Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev. Mol. Med. 11:e4.CrossRefGoogle Scholar
  26. 26.
    Hou Z, Matherly LH. (2014) Biology of the major facilitative folate transporters SLC19A1 and SLC46A1. Curr. Top. Membr. 73:175–204.CrossRefGoogle Scholar
  27. 27.
    Zhao R, Goldman ID. (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol. Aspects Med. 34:373–85.CrossRefGoogle Scholar
  28. 28.
    Zhao R, Goldman ID. (2007) The molecular identity and characterization of a Proton-coupled Folate Transporter—PCFT; biological ramifications and impact on the activity of pemetrexed. Cancer Metastasis Rev. 26:129–39.CrossRefGoogle Scholar
  29. 29.
    Sakamoto E, et al. (2008) Folylpolyglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem. Biophys. Res. Commun. 365:801–7.CrossRefGoogle Scholar
  30. 30.
    Kidd EA, et al. (2005) Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin. Cancer Res. 11:2612–9.CrossRefGoogle Scholar
  31. 31.
    Odin E, et al. (2003) Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin. Cancer Res. 9:6012–9.PubMedGoogle Scholar
  32. 32.
    Li H, Chung SJ, Shim CK. (2002) Characterization of the transport of uracil across Caco-2 and LLC-PK1 cell monolayers. Pharm. Res. 19:1495–501.CrossRefGoogle Scholar
  33. 33.
    Zhang S, et al. (2006) Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66:8847–57.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Elisabeth Odin
    • 1
  • Arvid Sondén
    • 2
  • Bengt Gustavsson
    • 1
  • Göran Carlsson
    • 1
  • Yvonne Wettergren
    • 1
  1. 1.Surgical-Oncology Laboratory Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital/ÖstraSahlgrenska Academy at University of GothenburgGothenburgSweden
  2. 2.Genomics and Bioinformatics Core FacilitiesSahlgrenska Academy at University of GothenburgGothenburgSweden

Personalised recommendations